key: cord-0052850-mggsgrv1
authors: nan
title: Acknowledgement to Referees
date: 2020-11-18
journal: Am J Cardiovasc Drugs
DOI: 10.1007/s40256-020-00452-8
sha: 6a21646186e6bc96330bd1c5372cc19484519a27
doc_id: 52850
cord_uid: mggsgrv1

nan

The high quality of the content published in the American Journal of Cardiovascular Drugs has been reflected in the most recent Impact Factor™ of 2.674 (placing the journal in the 2nd quartile of the 'Cardiac & Cardiovascular Systems' categories) and a CiteScore™ of 4.7 (placing the journal in the top quartile of the 'Cardiology and Cardiovascular Medicine' category). Further, the American Journal of Cardiovascular Drugs has published content in a timely manner, with an average time from submission to first decision of 28 days.

In 2021, the American Journal of Cardiovascular Drugs will continue to provide you with high interest, clinically relevant content in the field of cardiovascular therapy. I thank you for your continued support.

With best wishes, Amitabh Prakash

The COVID-19 pandemic has reinforced the importance of rapid and wide dissemination of high-quality information

Springer Nature is supporting the global response to COVID-19 by making all relevant content immediately and freely available. Indeed, the American Journal of Cardiovascular Drugs has published the following papers relevant to the COVID-19

Rubboli A for the Italian Study Group on Atherosclerosis, Thrombosis, Vascular Biology. Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology

Potential therapeutic roles for direct factor Xa inhibitors in coronavirus infections

Mortality and disease severity among COVID-19 patients receiving renin-angiotensin system inhibitors: a systematic review and meta-analysis

Amiodarone in the COVID-19 Era: treatment for symptomatic patients only, or drug to prevent infection?

Current overview on hypercoagulability in COVID-19

COVID-19 Pandemic: cardiovascular complications and future implications

Management of outpatient warfarin therapy amid COVID-19 pandemic: a practical guide

Cardiovascular disease and use of renin-angiotensin system inhibitors in COVID-19

Michal Tendera, Medical University of Silesia, Katowice, Poland